Results 221 to 230 of about 229,436 (314)

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

IDH2 lactylation regulates mitochondrial dysfunction injury induced by myocardial ischemia‑reperfusion via the AMPK signaling pathway. [PDF]

Int J Mol Med
Wang C, Shen S, Chen S, Lin J, Li S, Chen J, Cai S, Yuan X, Yang Z, Ding K, Xu L, Zhang L.   +11 more
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Histopathological Assessment of Myocardial Ischemia-Reperfusion Injury Using Transformer-Based Artificial Intelligence: Model Comparison Study. [PDF]

JMIR Med Inform
Liu C, Xu M, Lv Y, Zhu Z, Pan Y, Wang Y.
europepmc   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Screening and verification of drugs targeting myocardial ischemia-reperfusion injury. [PDF]

Medicine (Baltimore)
Liu Q, Tian Z, Mi S, Liang Z, Hang B.
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

NMRK2-YAP-NADK axis preserves redox protection against myocardial ischemia/reperfusion injury. [PDF]

Redox Biol
Zhang C, Wang J, Chi J, Liu ST, Meng XW, Li LG, Dong S, Cao H, Zhou XG, Zhang Y, Sun HY, Kang PP, Peng K, Ji FH.   +13 more
europepmc   +1 more source

Salvigenin alleviates ferroptosis and pyroptosis in myocardial ischemia/reperfusion models by inhibiting the NLRP3 pathway. [PDF]

Biomed Eng Online
Su W, Zhang S, Chen J, Sun J.
europepmc   +1 more source